LLY

What is LLY?

Eli Lilly and Company was founded back in 1876 by Colonel Eli Lilly, a Civil War veteran and pharmaceutical chemist who wanted to improve the quality of medicine. Headquartered in Indianapolis, the company has evolved from a small laboratory into one of the most valuable healthcare entities in the world. Their core business model revolves around intense research and development, focusing on discovering and manufacturing medicines that address some of the world's most significant health challenges.

The company’s product portfolio is currently dominated by its leadership in metabolic health. While they were the first to commercially produce insulin in the 1920s, they have recently shifted the landscape with tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management. These drugs have become massive revenue drivers. Beyond metabolic health, Lilly has a strong presence in oncology with Verzenio and is making significant strides in neuroscience with Donanemab, a treatment targeting Alzheimer’s disease.

Historically, Lilly has been a pioneer in industrial-scale manufacturing. They were instrumental in mass-producing the Salk polio vaccine and were early leaders in the production of penicillin. This legacy of scaling complex biologicals continues today as they invest billions into new manufacturing sites to meet the insatiable global demand for their GLP-1 receptor agonists.

Financially, Lilly is in a league of its own, boasting a market capitalization that has recently surpassed most of its traditional peers. Revenue growth is currently fueled by the rapid adoption of their new blockbuster drugs, providing the capital necessary to reinvest nearly 25% of sales back into R&D.

Looking ahead to 2026, the strategic outlook is centered on supply chain dominance and pipeline diversification. By 2026, many of their new production facilities will be fully operational, alleviating current supply constraints. Expect them to push further into oral versions of metabolic drugs and expand their immunology portfolio. With a robust balance sheet and a commanding lead in the obesity market, Lilly is positioned to remain a cornerstone of the healthcare sector for the foreseeable future.

What is the XTRM Indicator?

The XTRM (Extreme) Indicator is a proprietary momentum indicator that measures cumulative time spent in extreme territory. Unlike traditional oscillators like RSI that measure a snapshot in time, XTRM accumulates how long an asset remains in oversold or overbought conditions, providing a deeper understanding of momentum exhaustion.

For LLY, monitoring the XTRM indicator provides valuable insights into prolonged extreme conditions. When the XTRM drops significantly below zero (especially below -125), Eli Lilly & Co. has been in oversold territory for an extended period, suggesting potential for a reversal. Conversely, high positive XTRM values indicate extended overbought conditions.

Understanding LLY XTRM Signals

• Deep Oversold (XTRM below -125): When LLY XTRM falls below -125, it indicates prolonged time in extreme oversold conditions. This cumulative measure often provides stronger reversal signals than single-day oversold readings.
• Neutral Zone (XTRM near 0): When XTRM hovers around zero, LLY is in a balanced state without extended extreme conditions. This can indicate consolidation or indecision in the market.
• Overbought (XTRM above +10): An XTRM above +10 indicates LLY has been in overbought territory for an extended period, potentially signaling an overextended rally and increased risk of pullback.

Daily vs Weekly XTRM for LLY

This page displays both daily and weekly XTRM for LLY. The daily XTRM tracks short-term cumulative extremes, useful for identifying swing trading opportunities. The weekly XTRM provides a longer-term perspective on momentum exhaustion, helping investors spot major turning points.

By analyzing both timeframes together, you can identify when Eli Lilly & Co. is experiencing extreme conditions at multiple time scales, which often leads to the strongest reversal setups.

Historical XTRM Extreme Analysis

Above, we track historical instances when LLY XTRM dropped below -125 (extreme oversold territory). These periods represent times when Eli Lilly & Co. spent extended periods in oversold conditions, which historically have presented some of the best buying opportunities. Analyzing how LLY behaved after reaching these extreme XTRM levels can help inform future trading decisions.